SEQENS
Seqens is a global leader in pharmaceutical solutions and specialty ingredients, committed to innovation, sustainability, and responsible business practices. The company operates across multiple countries with a strong focus on R&D, manufacturing, and environmental and social responsibility, aiming to deliver high-quality products and solutions while minimizing its environmental impact.
Industries
Nr. of Employees
Very Large (1000+)
Products
Specialty enzymes for industrial biocatalysis
Natural and optimized enzyme products for use in bioconversion, synthesis and food/ingredient applications.
High‑value bioactive molecules
Manufacture and supply of bioactive proteins, peptides, polysaccharides, pigments, vitamins and other microbial metabolites.
Microorganism libraries and strain materials
Access to strain libraries, isolated strains and strain derivatives for screening, development and licensing.
Enzymatic conversion product for short‑chain fructo‑oligosaccharides (FOS)
An enzymatic bioconversion product for converting sucrose into short‑chain fructo‑oligosaccharides (scFOS) with high yield and low free fructose.
APIs, intermediates and excipients (multi‑market supply)
Range of chemical APIs, intermediates and excipients produced for pharmaceutical and specialty chemical markets, with options for bespoke/custom manufacturing.
Specialty enzymes for industrial biocatalysis
Natural and optimized enzyme products for use in bioconversion, synthesis and food/ingredient applications.
High‑value bioactive molecules
Manufacture and supply of bioactive proteins, peptides, polysaccharides, pigments, vitamins and other microbial metabolites.
Microorganism libraries and strain materials
Access to strain libraries, isolated strains and strain derivatives for screening, development and licensing.
Enzymatic conversion product for short‑chain fructo‑oligosaccharides (FOS)
An enzymatic bioconversion product for converting sucrose into short‑chain fructo‑oligosaccharides (scFOS) with high yield and low free fructose.
APIs, intermediates and excipients (multi‑market supply)
Range of chemical APIs, intermediates and excipients produced for pharmaceutical and specialty chemical markets, with options for bespoke/custom manufacturing.
Services
Collaborative R&D partnerships offering co‑development, joint projects and technology collaborations across pharma, cosmetics, food and specialty chemical markets.
Contract R&D and process development engagements covering enzyme screening, strain selection, fermentation development, biocatalytic route design and pilot scale‑up.
Manufacture of clinical‑grade cell therapy batches under GMP for early‑ and late‑stage clinical programs, including Phase 3 manufacturing capability.
Supply of natural or optimized enzymes and licensing of strains or strain‑derived materials for use in industrial bioconversion processes.
Laboratory services for early‑phase discovery, fine chemistry and cosmetic development provided through regional excellence centres.
Cradle‑to‑gate product carbon footprint calculations and sustainability assessments aligned with ISO 14067 and GHG Protocol Product Standard to support low‑carbon product offerings.
Collaborative R&D partnerships offering co‑development, joint projects and technology collaborations across pharma, cosmetics, food and specialty chemical markets.
Contract R&D and process development engagements covering enzyme screening, strain selection, fermentation development, biocatalytic route design and pilot scale‑up.
Manufacture of clinical‑grade cell therapy batches under GMP for early‑ and late‑stage clinical programs, including Phase 3 manufacturing capability.
Supply of natural or optimized enzymes and licensing of strains or strain‑derived materials for use in industrial bioconversion processes.
Laboratory services for early‑phase discovery, fine chemistry and cosmetic development provided through regional excellence centres.
Cradle‑to‑gate product carbon footprint calculations and sustainability assessments aligned with ISO 14067 and GHG Protocol Product Standard to support low‑carbon product offerings.
Expertise Areas
- Biocatalysis and enzyme engineering
- Precision fermentation and microbial engineering
- Bioprocess development and fermentation scale-up
- Active pharmaceutical ingredient (API) manufacturing
Key Technologies
- Biocatalysis
- Directed evolution
- Metabolic engineering
- Precision fermentation
News & Updates
Pascal Villemagne has been appointed CEO of Seqens, effective April 1, 2025.
Seqens' CELLforCURE will manufacture Galapagos’ CAR T-Cell Therapy candidates for upcoming trials.
Seqens Personal Care explores the science behind environmentally sensitive skin and introduces the active ingredient Sens’Flower (Crocus sativus Flower Extract).
Recognition for excellence in biocatalysis and enzyme development.
Recognition of sustainable practices and CSR performance.
Pascal Villemagne has been appointed CEO of Seqens, effective April 1, 2025.
Seqens' CELLforCURE will manufacture Galapagos’ CAR T-Cell Therapy candidates for upcoming trials.
Seqens Personal Care explores the science behind environmentally sensitive skin and introduces the active ingredient Sens’Flower (Crocus sativus Flower Extract).
Recognition for excellence in biocatalysis and enzyme development.
Recognition of sustainable practices and CSR performance.